• 腾博tengbo9885

    Nilotinib Hydrochloride

    TASIGNA®

    About TASIGNA®

    1. Marketed by Novartis Pharmaceuticals Corporation
    2. Orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor
    3. Treatment of adult and pediatric patients with newly diagnosed or treatment-resistant Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML)

    Approvals

    1. First E.U. approval: November 19, 2007
    2. First U.S. approval: October 29, 2007

    Constraint date forecast

    1. Patent expiry: 2023 (United States)
    2. Patent expiry: 2023 (European Union)
    3. Patent expiry: 2028 (Japan)

    The future of the generics landscape

    From innovation to bottom line

    Access our global intelligence, advanced analytics and global team of experts.

    Contact our team